SmithKline Beecham (Australia) Pty Ltd v Chipman

SmithKline Beecham (Australia) Pty Ltd sought judicial review of decisions made by the Therapeutic Goods Administration (TGA) and the Minister for Health and Ageing regarding the registration of a pharmaceutical product named Ausrox, which was a different salt of paroxetine. SmithKline argued that the registration of Ausrox, a competitor to its product Aropax, was flawed as it was based on the premise that Aropax and Ausrox were "pharmaceutical alternatives" without requiring proper pre-clinical or clinical trials for Ausrox. The court was required to determine whether the decisions to register Ausrox and to confirm its registration were legally sound, particularly regarding the reliance on data from Aropax and the lack of separate trials for Ausrox.

The court examined the basis for the decisions and the legal standards applicable under the Therapeutic Goods Act 1989. It considered whether the TGA and the Minister had acted within their statutory powers and whether the decisions were made without bias or error. The court found that the decisions to register Ausrox and to confirm its registration were made without requiring separate trials for Ausrox, and that the reliance on data from Aropax was not justified given the differences between the two products. The court concluded that the decisions were flawed due to the failure to conduct proper trials and the incorrect application of the "pharmaceutical alternatives" concept.

The court ordered the dismissal of the notice of motion filed by the fourth respondent and directed that the respondent pay the applicants’ costs of and incidental to the notice of motion. This decision underscores the importance of adhering to regulatory standards and conducting appropriate trials to ensure the safety and efficacy of pharmaceutical products.